Palvella Therapeutics, Inc. PVLA 深 沪
等待开盘 03-26 09:30:00 美东时间
120.39
+4.160
+3.58%
华盛通- 最 高123.94
- 今 开118.13
- 成交量 26.16万股
- 最 低 116.80
- 昨 收 116.23
- 总市值 16.18亿
- 52周最高 151.18
- 市盈率 静 --
- 换手率 1.95%
- 52周最低 18.225
- 委 比 -8.42%
- 总股本 1343.65万
- 历史最高 151.18
- 量 比 0.99
- 振 幅 6.14%
- 历史最低 11.17
- 每 手 1
- 风险率 34.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.
03-24 23:22
Palvella Therapeutics Secures European Patent Covering Lead QTORIN Rapamycin Gel
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular
03-16 19:37
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
美股牛股 | 绩优股大爆发！Clarivate大涨近40%；医药股PVLA涨超37%
绩优股大爆发！Clarivate大涨近40%，VIR涨超27%，是德科技涨超23%；核心产品试验迎突破性进展，医药股PVLA涨超37%>>
02-25 18:56
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Palvella Therapeutics Launches $150M Common Stock Offering
Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases
02-25 05:23
Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more th...
02-24 22:50
Palvella's QTORIN 3.9% Rapamycin Gel Demonstrates Strong Efficacy And Safety In Phase 3 Microcystic Lymphatic Malformations Trial, 95% Patients Improved At Week 24
Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA)Achieved statistical significance on
02-24 19:38
Palvella Announces Publication Of Systematic Review In Clinical And Experimental Dermatology Which Synthesizes Available Published Clinical Evidence On Off-Label Statin Use For Cutaneous Application In Porokeratosis
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosisPreliminary case reports suggesting clinical benefit underscore unmet need for development of a
02-02 20:36
